Alzheimer’s

Longeveron Inc (NASDAQ: LGVN) announced the publication of Phase 1 trial results of Lomecel-B on patients with mild Alzheimer's disease (AD) in the Alzheimer's & Dementia journal. The 33-subject trial met its primary endpoint, demonstrating that Lomecel-B was well...

This article was originally published on Cannabis.net and appears here with permission. There are over 5.8 million persons in the United States living with Alzheimer's disease, and of this number, 80% are above 75 years and older. Of the 50 million persons with dementia worldwide, about 70%...

Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has resubmitted its FDA supplemental marketing application for pimavanserin for hallucinations and delusions associated with Alzheimer's disease psychosis (ADP). This resubmission responds to the FDA's Complete Response Letter (CRL)...

Citi upgraded Eli Lilly And Co (NYSE: LLY) to Buy from Neutral with a price target of $265, up from $210, an upside of almost 16%. Analyst Andrew Baum says the upgrade is "predominately valuation driven," following the 15% selloff in the shares. Related Link: ...

Cassava Sciences Inc (NASDAQ: SAVA) announced an agreement with the FDA under a Special Protocol Assessment (SPA) for both of its pivotal Phase 3 trials for oral simufilam in treating Alzheimer's disease. The SPA document indicates that the regulator has reviewed and agreed to...

The Biden Administration has ruled out the nomination of acting FDA commissioner Janet Woodcock as permanent head of the agency, Bloomberg reported citing people familiar with the matter. The search continues for a permanent leader during this crucial period for full approval of COVID-19...

Synaptogenix Inc (NASDAQ: SNPX) has announced an update on its ongoing National Institutes of Health (NIH) sponsored Phase 2b trial of Bryostatin-1 for moderately severe Alzheimer's disease (AD). To date, the Company has dosed 58 of its target 100 patients. Additionally, the...

U.S. regulators are slated to decide by Monday whether to approve Biogen Inc’s (NASDAQ: BIIB) much-talked-about Alzheimer’s disease drug, aducanumab. The Decision: Wall Street analysts and industry observers are divided on its chances of approval. Some analysts are...

Annovis Bio Inc (NYSE: ANVS) has announced new results from a Phase 2 study evaluating its lead drug candidate, ANVS401, for Alzheimer's disease (AD), Parkinson's disease (PD). The data comes from 14 AD patients and 14 PD patients. Participants treated with ANVS401 for 25...

Biogen Inc (NASDAQ: BIIB) shares rallied strongly Tuesday after the biotech said it plans a regulatory filing for its Alzheimer's drug aducanumab, which the company had written off back in March. The Analysts Morgan Stanley analyst Matthew Harrison maintained an Underweight rating on...

Biotechs Axsome Therapeutics Inc (NASDAQ: AXSM) and Axovant Sciences Ltd (NASDAQ: AXON) were taking diverging paths Monday.  While shares of Axsome surged higher by nearly 8 percent, Axovant shares were down by more than 25 percent at the time of publication.  Positive Interim Results...